This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Kendall Law Group Investigating Javelin Pharmaceuticals, Inc. Merger Agreement

Kendall Law Group is investigating the merger of Javelin Pharmaceuticals, Inc. (AMEX: JAV) with Hospira, Inc. on behalf of Javelin shareholders. The national securities litigation firm is investigating whether a fair process was used by Javelin’s Board of Directors prior to entering into the merger agreement and whether they breached their fiduciary duties by not seeking a deal that would provide better value of the Company for shareholders. Javelin shareholders with questions or information on the firm’s investigation are encouraged to contact the Kendall Law Group at 877-744-3728 or by email at skendall@kendalllawgroup.com.

On April 19, 2010, Javelin announced that it had entered into an agreement to be acquired by Hospira in an all cash transaction valued at approximately $145 million. According to the agreement, shareholders will receive $2.20 per JAV share owned, just pennies over the closing price the past few days. Javelin stock has also closed at $2.12 on July 29, 2009 and $2.04 on September 22, 2009. The transaction is expected to move quickly, commencing within five business days and staying open for twenty.

Kendall Law Group, founded by a former federal judge, includes a former United States Attorney, prosecutors and securities lawyers who are experienced in complex securities litigation. The firm has been counsel in many merger and acquisition cases nationwide, including some of the largest transactions in the United States.



Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $130.28 0.00%
FB $81.53 0.00%
GOOG $565.06 0.00%
TSLA $218.42 0.00%
YHOO $44.52 0.00%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs